Indolent Non-Hodgkin's Lymphomas Completed Phase 1 Trials for Lenalidomide (DB00480)

Also known as: Indolent Non-Hodgkin Lymphoma / Indolent Non-Hodgkin's Lymphoma

IndicationStatusPhase
DBCOND0061053 (Indolent Non-Hodgkin's Lymphomas)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01088048Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic LeukemiaTreatment